Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)
The prerecorded fireside chat will be available starting on
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.
Investor and Media Inquiries:
Kathleen FarrenMerus N.V. IR/Corp Comms 617-230-4165 firstname.lastname@example.org